ArticleFrontiers in immunology2025
Identification of immunogenic cell death signature genes in hepatocellular carcinoma: from single-cell transcriptomics to
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of DYNLL1 and FGFR2 as potential apoptosis-associated biomarkers in HBV-related hepatocellular carcinoma.Discover oncology · 2026Article
- Integrative Multiomics Analysis Reveals a Cancer Stem Cell-Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) lacks reliable prognostic biomarkers for immunotherapy. Immunogenic cell death (ICD) represents a promising therapeutic target, but its comprehensive characterization in HCC remains unexplored. Methods: We performed multi-omics integration of single-cell RNA sequencing data from 7 HCC samples (GSE112271, 44,461 cells) with bulk transcriptomics from three independent cohorts (TCGA-HCC [n=371], GSE14520 [n=242], ICGC [n=445]). ICD activity was quantified using ssGSEA. We identified HCC-specific ICD-related (HCC-ICDR) genes via WGCNA and optimized a prognostic model by benchmarking machine learning algorithms. Experimental validation included functional assays using CLIC1 and NAP1L1 overexpression in HepG2 cells. Results: The ICD-based risk score (ICDRS) demonstrated superior prognostic accuracy (C-index=0.839), validated across cohorts. Single-cell profiling revealed macrophages exhibited the highest ICD activity. High-risk patients displayed immunosuppressive microenvironments with enriched Tregs, M0 macrophages, and neutrophils, alongside hyperactivated DNA repair and MYC signaling. Low-risk patients showed anti-tumor immunity with increased CD8+ T cells and M1 macrophages. ICDRS predicted differential therapeutic vulnerabilities: low-risk patients showed enhanced sensitivity to standard immunotherapy-compatible treatments including sorafenib and doxorubicin, while high-risk patients demonstrated preferential sensitivity to EGFR-targeted therapies. Experimental validation confirmed CLIC1 and NAP1L1 significantly promoted HCC malignant behaviors. Conclusions: We established the comprehensive ICD-based prognostic framework for HCC, revealing novel tumor-immune interactions and therapeutic vulnerabilities. This model provides robust stratification for immunotherapy selection and advances precision medicine in HCC management. Future clinical translation includes prospective validation and development of companion diagnostics, offering potential pathways for personalized HCC treatment implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.